JerMa88/BMC_Gastroenterology_Peer_Reviews huggingface dataset:
Review for 10.1186/s12876-024-03491-6 (2024)

Title: Celiac disease autoimmunity among Nigerian children and adolescents with type 1
diabetes mellitus
Version: 4 Date: 05 Jul 2024
Reviewer:  angela spinola
Reviewer's report:
Dear authors, I appreciate your work on this study. Your study seems to be well done, and it
tackles a crucial health problem, Celiac disease, among children with type 1 diabetes in Nigeria.
It offers a clear contribution, such as a clear recommendation for screening and early diagnosis
of CD in children with T1DM, especially highlighting the need for more awareness among
healthcare providers. However, some areas could be improved to make the study more robust.
1-As you know, the confirmatory biopsies would increase the diagnostic precision, besides the
importance of the antibodies  2-I think a longitudinal study design would reveal the impact
of CD on the quality of life of T1DM patients. 3-Having a control group of children without
T1DM could help compare the prevalence of CD in the general population with those with
T1DM. 4-Detailed Symptom Analysis: A more detailed analysis of gastrointestinal and other
symptoms could help find specific clinical markers indicative of CD in T1DM patients. 5—
Diabetes control in the group of significantly affected patients is essential to provide a clinical
clue for the diagnosis. 6- I missed family history about other autoimmune diseases and CD. 7-
In the discussion, a better analysis of possible genetic differences between Nigeria populations
in the North is needed  8- Writing needs corrections
Your study needed these details to show a difference. Otherwise, you only reported the frequency
of CD in Nigeria, which is not new to research. Previous studies did the same thing, so you did
not find any new data. If you could compare the genetics of the populations or the environment,
you could offer new insights and contribute to this field.
Review for 10.1186/s12876-024-03491-6 (2024)

Title: Celiac disease autoimmunity among Nigerian children and adolescents with type 1
diabetes mellitus
Version: 5 Date: 06 Aug 2024
Reviewer:  Glauce Hiromi Yonamine
Reviewer's report:
The authors have revised the manuscript and it is improved. In this version, the authors stated that
they used the term "celiac autoimmunity" instead of "celiac disease". The definition of "celiac
autoimmunity" is used in the literature? I think the manuscript is confusing to the reader because
both terms are used, and the term "prevalence of seropositive CD" is also used. I recommend
revising the manuscript for the correct usage of the terms. Example: Title, results subtitles
"Prevalence of celiac disease in children with T1DM" and "Clinical characteristics of study
participants with or without celiac disease".
Review for 10.1186/s12876-024-03491-6 (2024)

Title: Celiac disease autoimmunity among Nigerian children and adolescents with type 1
diabetes mellitus
Version: 5 Date: 31 Aug 2024
Reviewer's report:
The authors from Nigeria reported celiac seropositivity (not the actual biopsy-confirmed CD) in
6/104 diabetic children (T1DM), approximately 6% and 4/6 cases had nonspecific GI symptoms
but only one child (<1% prevalence of biopsy-confirmed CD in this cohort or almost 2% if
counted patient No. 4 in Table 2 as CD) underwent duodenal biopsy, while the other 4 out of 5
children should had undergone duodenal biopsy (patients No .2, 3, 5, 6from table 2).
I feel that the study had some important limitations.
1. For the above reason, the title of this important study should be changed to "
Celiac seropositivity in ....." not celiac disease itself as most seropositive cases did not undergo
duodenal biopsy.  Information on the limitations with regards to duodenal biopsy to confirm CD
should be initially mentioned in the Abstract for transparency.
2. Nausea, vomiting, diarrhea, bloating are all nonspecific GI symptoms that can occur in IBS,
FGID, lactose intolerance, bacterial overgrowth, or even diabetic neuropathy of the GI tract
itself, etc. All these conditions may even be more common in Nigeria (and many other countries
in the world). Please comment on this point. Were there any screening questions or test such as
hydrogen breath test to rule out  the aforementioned condition.
A  previous study  (https://pubmed.ncbi.nlm.nih.gov/26508189/) also reported that diabetic
children with celiac seropositivity actually had less prevalent GI symptoms.  It may be
worthwhile to discuss this issue  with the similar/different previous studies.
3. Please explain the biological plausibility of gender predilection in CD-associated T1DM (not
just the CD itself), or if this just occurred by chance.
Minor points
- What is the definition of 'rather low TTG' or moderate elevation? Please define in the Methods.
- No need add Figure 1 to the study as it does not add much value to the reported data esp. with
Marsh I ?  Even more confused as the manuscript text and Table 2 (patient 1) explained the
histopathology of Marsh III due to the blunted villi but the Figure 1 exhibits Marsh I - please
clarify (or just consider dropping the Figure out).
Review for 10.1186/s12876-024-03491-6 (2024)

Title: Celiac disease autoimmunity among Nigerian children and adolescents with type 1
diabetes mellitus
Version: 5 Date: 02 Sep 2024
Reviewer's report:
Dear Authors,
Thank you very much for re-submitting your work, and giving me the opportunity to review
the revised manuscript.
There were some important issues in the initial manuscript that were addressed by the authors.
Majority of comments were included in the revised manuscript, and some were explained in
more detail in Authors response.
I do still have some comments that should be addressed further.
The decision to perform IgA EMA in IgA deficient patients is a limitation of the study. Despite
some reports in the literature, that patients with negative IgA TGA, were later found to be
positive for IgA EMA, majority of IgA deficient patients will not be able to produce IgA EMA,
so it would be appropriate in these patients to perform either of the IgG tests: EMA, TGA or
DGP. By performing IgA EMA in IgA deficient patients there is a higher risk of false negative
results.
Please make sure to provide the information that total IgA in children varies with age and that
reference ranges of lower limit of normality for total IgA are lower for smaller children than
for older ones.
Please check again for the use of CD and celiac autoimmunity.
Refrain from using the term CD if patients were not diagnosed according to currently available
guidelines (high Ab titers and double serology or positive titer and appropriate histopathology)
»Prevalence of celiac disease in children with T1DM«
»The study found that the prevalence of seropositive CD among Nigerian children and
adolescents«
In this respect it is also suggested to include the term Celiac disease autoimmunity in the title
of the manuscript.
Instead of using the term “celiac antibodies” it would be appropriate to use either “celiac disease
specific antibodies” or perhaps “markers of celiac autoimmunity”
Review for 10.1186/s12876-024-03491-6 (2024)

Title: Celiac disease autoimmunity among Nigerian children and adolescents with type 1
diabetes mellitus
Version: 8 Date: 21 Oct 2024
Reviewer's report:
Thanks authors for the study. The authors did  an appropriate point-by-point response to  the
reviewers. I think that it will contribute to the literature
Review for 10.1186/s12876-024-03488-1 (2024)

Title: Impact of Sociodemographic Disparities on Sarcopenia, Telomere Length, and Mortality
in Patients with Liver Disease in the US Population
Version: 2 Date: 10 Sep 2024
Reviewer's report:
The paper is well written and the statistical analysis is sound, following protocols recommended
for adjusting raw data.  There have been papers already evaluating either 1. sarcopenia on
outcomes in liver disease and 2. telomere length on outcomes in liver disease
The main issue with the current article is that age is a significant factor influencing both muscle
mass and telomere length.
The overall older mean age of those with sarcopenia illustrates this expected data.  It makes it
much more difficult to interpret data such as "Applying the ALM definition, sarcopenia was
present in 10.2% of patients with ALD, 20.5% of patients with VLD, 13.1% of patients with
NLD, 7.7% of patients with MASLD, and 12.8% of patients with OLD " without knowing the
mean age of each group.
The same would be notable for age and telomere length.  I am curious regarding the findings
of "Longer telomeres were generally associated with increased mortality at younger ages,
especially in those with sarcopenia. However, at older ages, longer telomeres were associated
with decreased mortality in those without sarcopenia. "  I would wonder what is the significance
of this data in a paper regarding liver disease?  The explanation in the discussion references a
higher rate of cancers with germline genetic variation.  I would also assume little mortality in
this group.  I am not sure what this data means.  Was this seen in the non-liver disease population
as well?
Review for 10.1186/s12876-024-03510-6 (2024)

Title: Impact of perioperative immunonutrition on postoperative outcomes in
pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled
trials.
Version: 0 Date: 29 Aug 2024
Reviewer's report:
Thank you so much for such paper.
first of all paper does not looks pretty and novel .There are a lots language errors .I think there
are some papers very same .
Review for 10.1186/s12876-024-03510-6 (2024)

Title: Impact of perioperative immunonutrition on postoperative outcomes in
pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled
trials.
Version: 0 Date: 02 Sep 2024
Reviewer's report:
The manuscript titled "Impact of Perioperative Immunonutrition on Postoperative Outcomes in
Pancreaticoduodenectomy: A Systematic Review and Meta-Analysis of Randomized Controlled
Trials" has significant potential but requires extensive revisions before it can be considered for
review. The English language throughout the manuscript is poor, with numerous grammatical
errors, awkward phrasing, and inappropriate word choices that hinder comprehension. A
comprehensive language edit is necessary, ideally by a native English speaker or professional
editing service, to enhance clarity and readability. Additionally, the manuscript's formatting does
not adhere to standard guidelines, with inconsistencies. The presence of numerous typographical
errors also suggests a need for careful proofreading to correct spelling, punctuation, and
abbreviations.
Review for 10.1186/s12876-024-03510-6 (2024)

Title: Impact of perioperative immunonutrition on postoperative outcomes in
pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled
trials.
Version: 0 Date: 11 Sep 2024
Reviewer:  Giuseppe Esposito
Reviewer's report:
I am grateful for the opportunity to review the manuscript.
I recommend that BMC Gastroenterology accept for publication this meta-analysis on
the effect of immunonutrition on the postoperative outcome of patients who underwent
pancreaticoduodenectomy.
The Materials and Methods section is comprehensive and meticulous, particularly with regard to
the precise evaluation of the risk of bias and the assessment of the included studies. Furthermore,
the results of the meta-analysis are robust, reflecting the high quality of the included studies, all
of which were randomised controlled trials.
In the case of continuous data provided as median and range (LOS in Fig. 6 for Gade et al. 2016
and for Joe et al. 2006), the method employed by the author to estimate the mean and standard
deviation, which the author included in the meta-analysis (Fig. 6), should be reported in the
statistical analysis section.
Therefore, if the method described by Hozo et al. (*) is employed to estimate the mean and
standard deviation in Fig. 6:
- the estimated mean of the Intervention Group of Gade et al. 2016 should be 14.5
- the estimated mean of the Control Group of Gade et al. 2016 should be 17.5
- the SD of the Control Group in Jo et al. 2006 should be 9.25 or 9.3
*https://doi.org/10.1186/1471-2288-5-13
Hozo, S. P., Djulbegovic, B. & Hozo, I. Estimating the mean and variance from the median,
range, and the size of a sample. BMC Medical Research Methodology 5, 13 (2005).
Furthermore, in the case of continuous data presented as a median and interquartile range (IQR),
the mean and standard deviation should be estimated using the methodologies outlined by Luo
et al. and Wan et al.
- Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample
size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 27(6):1785–805
- Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation
from the sample size, median, range and/or interquartile range. BMC Med Res Methodol
14(1):135
Finally, the total number of patient included in the Control Group of Gianotti et al. 2000 should
be modified in 73 (not 70) , in accordance with the original paper.
The manuscript is well-written and merits publication in BMC Gastroenterology.
Review for 10.1186/s12876-024-03510-6 (2024)

Title: Impact of perioperative immunonutrition on postoperative outcomes in
pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled
trials.
Version: 2 Date: 23 Sep 2024
Reviewer:  Giuseppe Esposito
Reviewer's report:
Thank you for your revisions.
Review for 10.1186/s12876-024-03510-6 (2024)

Title: Impact of perioperative immunonutrition on postoperative outcomes in
pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled
trials.
Version: 2 Date: 15 Oct 2024
Reviewer's report:
This systematic review and meta-analysis included a total of 10 RCTs with 574 patients
underwent pancreaticoduodenectomy found that perioperative immunonutrition can reduce
postoperative infection-related complications
A literature review using the keywords “pancreaticoduodenectomy” and “immunonutrition”
revealed three systematic review and meta-analysis in the past three years. Can the authors justify
the need for a new systematic review and meta-analysis and include it in the discussion section?
https://pubmed.ncbi.nlm.nih.gov/37069556/
https://pubmed.ncbi.nlm.nih.gov/32613544/
https://pubmed.ncbi.nlm.nih.gov/34836308/
In the literature retrieval strategy subsection, materials and methods section, the elaboration of
the search strategy is insufficient. The authors will need to publish the search strategy used in
the individual database.
Under the statistical analysis subsection, materials and methods section, the selection of a
computational model should be done a priori depending on whether all studies share a true effect
size. The authors adopted the wrong practice of starting with a fixed-effect model and then
switching to a random-effects model if the test of homogeneity is statistically significant.
Under the statistical analysis subsection, materials and methods section,  the authors stated
“When more than five studies were included, a funnel plot was used to assess potential
publication bias. P < 0.05 is considered to indicate a significant overall effect.”. How did the
authors arrive at five studies? Is there any evidence to support this practice?
Kindly revise Figure 1. The records excluded and reasons to exclude full articles should be one
level higher.
Under discussion section, the authors used “by performing a more exhaustive literature search”.
This statement is relative to which study? The existing systematic review and meta-analysis
in the literature already included all the RCTs in this present study which reached the similar
conclusions.
Review for 10.1186/s12876-024-03510-6 (2024)

Title: Impact of perioperative immunonutrition on postoperative outcomes in
pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled
trials.
Version: 2 Date: 15 Oct 2024
Reviewer:  Monish Karunakaran
Reviewer's report:
I really enjoyed reading the manuscript and would like to offer the following comments.
1. While introducing the premise of the study, I would urge the authors to state the important role
played by the ERAS protocols in improving the post-operative recovery of patients undergoing
pancreatoduodenectomy in the Introduction section.
2. In a meta-analysis by Probst et al (PMID: 28940219), immuno-nutrition was associated with
reduced overall and infectious complications in 83 RCTs with 7116 patients (grade of evidence
low to moderate). Not only these effects vanish after excluding trials at high risk of bias,
alarmingly, non-industry-funded trials did not display positive effects for overall complications,
whereas industry-funded reported large effects.
Did the authors notice similar trend in the current study? If not already done, is it possible to do
a segregated analysis within the current meta-analysis in pancreatoduodenectomy?
Review for 10.1186/s12876-024-03510-6 (2024)

Title: Impact of perioperative immunonutrition on postoperative outcomes in
pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled
trials.
Version: 3 Date: 21 Oct 2024
Reviewer's report:
I thank the authors for the reply to comments highlighted. Overall, I still have concerns regarding
the computational model chosen. While I acknowledge the authors efforts in conducting this
study, I have doubts regarding the need for a new systematic review given significant overlap
between the previous studies performed. I will leave the final decision to the editor to decide.
Review for 10.1186/s12876-024-03510-6 (2024)

Title: Impact of perioperative immunonutrition on postoperative outcomes in
pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled
trials.
Version: 3 Date: 21 Oct 2024
Reviewer:  Monish Karunakaran
Reviewer's report:
Thank you for the responses
Review for 10.1186/s12876-024-03510-6 (2024)

Title: Impact of perioperative immunonutrition on postoperative outcomes in
pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled
trials.
Version: 3 Date: 23 Oct 2024
Reviewer:  Giuseppe Esposito
Reviewer's report:
The meta-analysis is well done
Review for 10.1186/s12876-024-03510-6 (2024)

Title: Impact of perioperative immunonutrition on postoperative outcomes in
pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled
trials.
Version: 4 Date: 25 Oct 2024
Reviewer:  Monish Karunakaran
Reviewer's report:
Thank you for the revisions.
Review for 10.1186/s12876-024-03480-9 (2024)

Title: The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A
systematic review and meta-analysis
Version: 0 Date: 03 Jul 2024
Reviewer's report:
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A new
systematic review and meta-analysis
The authors conducted a systematic review and meta-analysis to assess the efficacy of the
infliximab biosimilar CT-P13 in patients with inflammatory bowel disease. While the study
addresses an interesting topic, it requires substantial revision.
Suggestions for Revision:
1) Remove the word “New” from the title.
2) In the introduction, it was stated that “at present, the principal treatment methods include
general anti-inflammatory therapy, hormonal anti-inflammatory therapy, immunosuppressants,
biological agents, fecal microbial transplantation, and surgical treatment”.
• Please clarify what is meant by hormonal anti-inflammatory therapy
• Fecal microbial transplantation is still considered experimental treatment for IBD
3) In the methods section, it is mentioned that the literature search included “PubMed, Embase,
Cochrane, Web of Science, and other databases”. Please specify which other databases were
searched.
4) The search was performed in June 2022. As this was over two years ago, it is recommended
to update the search to include more recent studies.
5) Please revise Forrest plots. They are currently confusing and, in some cases, incorrectly
labelled.
6) The results section is difficult to follow. Consider reporting only the overall OR for each
outcome and presenting the subgroup results (ie. 8-14 weeks, 24-30 weeks, 48-54 weeks,
7) Please describe the use of subgroups in the methods section.
8) Please provide more detail on how sensitivity analyses were conducted for age, sex,
concomitant medications, disease activity etc., as well as the results of these analyses.
9) Did all studies use the same dose and frequency of CT-P13? If not, explain how differences
were addressed.
10) Extensive editing is needed to improve the clarity of the manuscript.
Review for 10.1186/s12876-024-03480-9 (2024)

Title: The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A
systematic review and meta-analysis
Version: 0 Date: 03 Jul 2024
Reviewer:  Mukesh Ranjan
Reviewer's report:
I congratulate the authors for their effort in gathering recent evidence for biosimilar and
originator molecules. Though the findings are similar to previous studies, the current study is
commendable as it has also looked at the mucosal healing rates in UC. But the study mostly
relies on the results of observational studies as the number of RCTs are very few. However, it
is a nice study. There are certain suggestions that need to be addressed.
• Abstract: conclusion “CT-P13 is effective in the short and long term”- The result of the abstract
does not have data on follow up or mean duration of remission. So, the efficacy in long term
does not get supported.
• Introduction: “Another meta-analysis conducted after two years reported the same result.”
Please provide a reference for this statement.
• Methods: The authors are requested to provide the criteria they assumed for clinical response,
clinical remission in various studies. It is possible that not all the studies have uniform
definitions. In this regard, it becomes important to provide a definition considered for these
outcomes (clinical remission and response). In fact, these definitions might be a good tool to
include or exclude studies.
• Results: “The 26 included clinical trials studies were classified according to whether or not
patients underwent switching of the therapeutic agent.”- I think this is a mistake. The number
included is 29.
• Results: Did the RCTs look at treatment naïve and transitioned groups separately?
Review for 10.1186/s12876-024-03480-9 (2024)

Title: The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A
systematic review and meta-analysis
Version: 4 Date: 31 Aug 2024
Reviewer's report:
Thank you for your revisions. The manuscript is significantly improved, but a few areas still
need correction.
1. Thanks for the clarification regarding hormonal anti-inflammatory therapy. Typically, we
refer to these medications simply as corticosteroids instead of “glucocorticoid hormonal anti-
inflammatory therapy”.
2. Results section of the abstract:
a) What do you mean by “Crohn’s disease who were naïve”? Do you mean naïve to therapy or
naïve to biologics.
b) “Ulcerative colitis who were naïve to biological agents” – In the main text, it was stated that
these patients were naïve to all treatment not just to biologics. Please clarify.
c) Please double check all the numbers provided in the abstract to ensure accuracy. For example,
it is stated in the abstract that “clinical response rate of patients with Crohn’s disease who were
naïve was 0.80 (95% CI, 0.75-0.85)”. However, in the main text, it is stated that “the total pooled
rate of clinical response rates on patients with CD was 0.81%, 95% CI (0.76 to 0.85).”
d) Please provide the follow up interval for the results reported in the abstract
3. Conclusion sentence of the abstract needs to be more informative.
Review for 10.1186/s12876-024-03480-9 (2024)

Title: The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A
systematic review and meta-analysis
Version: 4 Date: 02 Sep 2024
Reviewer:  Mukesh Ranjan
Reviewer's report:
I want to congratulate authors for a good work.
Review for 10.1186/s12876-024-03500-8 (2024)

Title: Advantages Comparison of Peritoneal Drainage versus No Drainage after Laparoscopic
Appendectomy for Complicated Appendicitis: A Meta-analysis
Version: 3 Date: 08 Sep 2024
Reviewer:  Ali Yasen Y. Mohamedahmed
Reviewer's report:
Thank you for the opportunity to review this systematic review and meta-analysis. It's well
conducted with a reasonable methodology and statistics. However, I have one major concern
which is combining complicated and complicated appendicitis in the analysis. Usually, a
peritoneal drain is used when there is perforated appendicitis or an appendicular mass. I believe
authors need to address this either by excluding simple, uncomplicated appendicitis or by
creating a subgroup analysis for studies that only included complicated appendicitis.
Also, in the discussion, the authors mentioned: ( Currently, there are limited meta-analyses
assessing the utility of PD following laparoscopic appendectomy.) There are at least two other
meta-analyses on this topic (https://doi.org/10.3389/fsurg.2022.1086877) and (DOI: 10.7759/
cureus.32018 ); please explain what this study is adding to the literature if the view of already
available meta-analysis.
Review for 10.1186/s12876-024-03500-8 (2024)

Title: Advantages Comparison of Peritoneal Drainage versus No Drainage after Laparoscopic
Appendectomy for Complicated Appendicitis: A Meta-analysis
Version: 3 Date: 15 Sep 2024
Reviewer's report:
Thank you for the opportunity to review this meta-analysis. It addresses a highly relevant topic
(evidence for drainage in laparoscopic appendectomy). The strengths of this meta-analysis lie,
on the one hand, in the selection of the studies considered (n = 14) and, on the other hand,
in the careful statistical analysis. The accompanying figures are clearly structured and help to
understand the results.
Despite all the existing limitations (inclusion of many retrospective studies, n = 11), which are
also discussed by the authors, I consider the meta-analysis to be an important contribution to
the topic. Accept.
Review for 10.1186/s12876-024-03500-8 (2024)

Title: Advantages Comparison of Peritoneal Drainage versus No Drainage after Laparoscopic
Appendectomy for Complicated Appendicitis: A Meta-analysis
Version: 4 Date: 20 Oct 2024
Reviewer's report:
Dear authors,
You have carefully completed and revised your manuscript in accordance with the instructions
of all reviewers. The quality of your meta-analysis has been further improved by focusing on
complicated appendicitis. This is a study on a highly relevant topic. Unfortunately, retrospetitive
studies have been carried out on this issue for the most part. You have addressed the issue very
well with the methodology you have used, so that in the end a general recommendation can be
made to not use a drain in complicated appendicitis.
One more personal comment (own opinion): In a) cholecystectomy and b) pancreatic resections,
drains are predominantly inserted for a different purpose, namely a) early detection of a bile
leak or b) a pancreatic fistula. If the drainage secretion is unremarkable (no bile, no elevated
pancreatic enzymes), the drain can be removed at an early stage. If there are elevated pancreatic
enzymes or bile in the drainage secretion, the drainage can drain this off, which means that
conservative treatment is possible in most cases. Therefore, the indications for drainage in
appendectomy, cholecystectomy and pancreatic resection are hardly comparable.
I had already recommended acceptance for publication in my first evaluation. I stand by this:
accept.
Review for 10.1186/s12876-024-03500-8 (2024)

Title: Advantages Comparison of Peritoneal Drainage versus No Drainage after Laparoscopic
Appendectomy for Complicated Appendicitis: A Meta-analysis
Version: 4 Date: 27 Oct 2024
Reviewer:  Claudia Rudroff
Reviewer's report:
Thank you for the opportunity to review the revised manuscript. The authors have made notable
improvements , enhancing the robustness of their findings. The manuscript now provides a
more precise evaluation of the role of peritoneal drainage in complicated appendicitis. These
amendments, along with the thorough exploration of heterogeneity and additional patient-
centered metrics, have significantly strengthened the clarity and interpretive power of the study.
The manuscript conclusions contribute  to clinical practice. Well done.
Review for 10.1186/s12876-024-03505-3 (2024)

Title: The longterm impact of post-cholecystectomy major bile duct injury on liver stiffness.
Version: 3 Date: 19 Jul 2024
Reviewer:  Tri Hening Rahayatri
Reviewer's report:
1. Inclusion and exclusion criteria should be written clearly described in this manuscript. Were
the subjects had to be following laparoscopy? And all the subjects should be type E Strassberg
classification?
2. What was the reason of repairing the bile duct injury using hepaticojejunostomy instead of
primary repair?
3. In the result, the author mentioned that 84.2% (n = 16) underwent primary
hepaticojejunostomy while 15.8% (n = 3) underwent revision hepaticojejunostomy. Please
explain whether the 3 subjects had redo revision or not, or explain the different between the
two group.
4.  In 95% (n = 18) patients HJ was performed as a second surgery to the cholecystectomy. What
was the other procedure that caused bile duct injury? If this case control subjected to the patients
post-laparoscopy cholecystectomy, it has to be mentioned clearly, and no other procedure should
be included.
5. Please explain why in the table 1 diabetes encountered in 7 18.4% of control group and 315.8%
in test group (not 100%).
6. In the table 1 please clarify the F0/F1 etc. It should be written Metavir scoring, and below it
could be add the stage as example:
Metavir scoring
F0/F1
F2
F3/F4
Review for 10.1186/s12876-024-03505-3 (2024)

Title: The longterm impact of post-cholecystectomy major bile duct injury on liver stiffness.
Version: 3 Date: 26 Jul 2024
Reviewer's report:
I appreciate the opportunity to review this interesting article. In the paper, the authors provide
a thorough examination of the long-term impact of hepaticojejunostomy on liver stiffness and
fibrosis. They conclude that while major bile duct injury (BDI) repair using hepaticojejunostomy
does not show a significant difference in overall liver fibrosis compared to controls, the presence
of right hepatic artery injury or anastomotic stricture may increase the risk of significant fibrosis.
Bile duct injury, which is difficult to completely eliminate, is a serious complication in biliary
surgeries such as cholecystectomy. Moreover, managing biliary injury is complex and requires
careful, individualized planning and coordination to address both the immediate surgical needs
and the long-term implications for patient health.
Although the theme is interesting, aspects of the study design, such as the study population,
inclusion criteria, and methods of comparison, are not well described, making it difficult to
clearly understand the focus of the study. These are fundamental aspects of the research. Unless
they are clarified, it may be difficult to publish the article.
Review for 10.1186/s12876-024-03505-3 (2024)

Title: The longterm impact of post-cholecystectomy major bile duct injury on liver stiffness.
Version: 4 Date: 13 Aug 2024
Reviewer:  Tri Hening Rahayatri
Reviewer's report:
1. Based on research methods, this research was conducted on patients who underwent open and
conventional procedures. However, the research background only mention laparoscopy. Please
correct the introduction.
2. The manuscript improvements are good. However, to produce a better manuscript, grammar
should be improved further.
3. This sentence on page 6 should be revised: Overall, there were 5 patients who developed
26.3% (n=5) anastomotic site strictures including two newly developed strictures following
repair in the center.
4. The first sentence on discussion should be clarified: In this cohort of 50 patients with BDI,
20 had Strasberg E injuries. Of these patients 21.1% had F3/4 fibrosis.
There were only 19 patients with BDI included in the study
Review for 10.1186/s12876-024-03505-3 (2024)

Title: The longterm impact of post-cholecystectomy major bile duct injury on liver stiffness.
Version: 4 Date: 01 Sep 2024
Reviewer's report:
The  authors have done an interesting study looking at the long term impact of bile duct injuries
following laparoscopic/ open cholecystectomies on liver fibrosis. patients with a 6 month
followup have undergone fibroscan. Thee authors have concluded that hepaticojejunostomy
after bile duct injury does not cause long term liver damage. Complex bile duct injuries such as
those with right hepatic artery injury and patient's developing strictures may develop significant
fibrosis. Although the number of patients in the study is small and the followup could have been
longer, I think it's an important study.
Review for 10.1186/s12876-024-03505-3 (2024)

Title: The longterm impact of post-cholecystectomy major bile duct injury on liver stiffness.
Version: 5 Date: 16 Sep 2024
Reviewer:  Tri Hening Rahayatri
Reviewer's report:
This manuscript has good content, is in accordance with writing rules, and has produced
significance conclusion.
Review for 10.1186/s12876-024-03505-3 (2024)

Title: The longterm impact of post-cholecystectomy major bile duct injury on liver stiffness.
Version: 5 Date: 21 Sep 2024
Reviewer's report:
1. It is an important study, Well done!
2. Hepatic fibrosis is known complication after severe bile duct injuries
3. Fibroscan looked at the right lobe following RHA injury,  Fibrosis is expected as mentioned
by the author- how would this have made a difference in the outcome ? Were the Liver functions
severely compromised after 6 months ?
3. please include the no of patients who underwent HJ in the table
4. 16 patients were offered HJ ? did they undergo the procedure? Please correct this
5. total patients with anastomotic stricture were (6+3) 9 and without anastomotic stricture were
(9+1) 10 , that makes it 19 patients , while the surgery was offered to 16 patients, could you
clarify this please.
6. Was there any other form of radiological imaging done around the time of fibroscan? Any
relevant or significant changes from the time of injury or pre operative studies.
7. Any endoscopic interventions attempted for BDI injuries ?
8. Were there any other complications other than cholangitis among these patients ? ( such as
abscess, necrosis)
9.   Conclusion - "Major BDI repair demonstrates comparable liver fibrosis between patients and
healthy controls. Measuring liver fibrosis could be valuable in the presence of arterial injuries
or anastomotic stricture" - could mean early HJ in all major BDIs provides comparable  liver
fibrosis to controls- please clarify, and how is it valuable  with a known cause and effect ?
Review for 10.1186/s12876-024-03505-3 (2024)

Title: The longterm impact of post-cholecystectomy major bile duct injury on liver stiffness.
Version: 7 Date: 10 Nov 2024
Reviewer's report:
The authors have made all the changes suggested by the reviewers. It is a well conducted study
looking at  long term impact of bile duct injury with or without vascular injury.
Review for 10.1186/s12876-024-03499-y (2024)

Title: 7-Hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK
pathway and alleviating gut microbiota dysbiosis
Version: 5 Date: 09 Aug 2024
Reviewer's report:
Useful scientific work and I have some suggestions to be your manuscript more clear and
interesting for readers:
#2.1 Succinctly state the DAI evaluation method.
#2.10 The 16S analysis needs to be expanded upon, there are many parameters in 16S analyses
and the reader is told limited sequencing method.
#3.1 Kindly make appropriate description of DAI. If applicable add in the section, the H&E
score, or mark out colonic crypts and epithelial cells with arrows in Figure 1F.
#3.5.5 It is difficult to draw conclusions of PCoA and NMDS. Suggest accurate representation.
#Improve the discussion section.
#Abbreviations of the same word are found both in the methods and results paragraphs. I also
found some editing errors in the manuscript. Kindly revised the manuscript carefully.
Review for 10.1186/s12876-024-03499-y (2024)

Title: 7-Hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK
pathway and alleviating gut microbiota dysbiosis
Version: 5 Date: 29 Aug 2024
Reviewer's report:
In the manuscript titled "7-Hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting
the MAPK pathway and alleviating gut microbiota dysbiosis," the authors conclude that the
protective effect of 7-Hydroxycoumarin on DSS-induced ulcerative colitis in mice is mediated
through the inhibition of the MAPK signaling pathway in the colon and the restoration of
intestinal microbiota composition. However, before this manuscript can be considered for
publication, several critical issues need to be addressed to enhance the overall quality of the
study:
Consideration of NF-#B Activation: Since NF-#B is a crucial transcription factor involved in
the production of proinflammatory cytokines, it would be valuable to investigate the potential
effects of 7-Hydroxycoumarin on NF-#B activation.
Selection of Male Mice: The authors should clarify why only male mice were used in this study,
considering that sex differences can influence disease outcomes and drug efficacy.
Impact on Epithelial Barrier Function: Disruption of the epithelial barrier is a hallmark of
ulcerative colitis. The authors should examine whether 7-Hydroxycoumarin has any positive
effects on the expression or function of tight junction proteins.
Inclusion of Additional Colitis Models: To strengthen the findings, the study would benefit from
the inclusion of other colitis models beyond DSS-induced colitis, which would provide a broader
perspective on the therapeutic potential of 7-Hydroxycoumarin.
Improvement of Histological Images: The H&E images in Figure 1F need improvement to better
illustrate the effects of different doses of 7-Hydroxycoumarin on epithelial structure. The current
images primarily highlight the underlying lamina propria and submucosa rather than the crypt-
villus axis.
Review for 10.1186/s12876-024-03499-y (2024)

Title: 7-Hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK
pathway and alleviating gut microbiota dysbiosis
Version: 6 Date: 31 Oct 2024
Reviewer's report:
Thank you for submitting the revised version of your manuscript. I have carefully reviewed the
changes made in response to the previous round of reviews. I am pleased to inform you that
you have adequately addressed all the concerns raised during the review process. Thank you for
your diligent work in improving the manuscript. I look forward to seeing your work in print.
Review for 10.1186/s12876-024-03498-z (2024)

Title: The mechanism of transcutaneous gastric pacing treatment on gastrointestinal motility
recovery and inflammation improvement in early-stage acute pancreatitis patients
Version: 0 Date: 03 Oct 2024
Reviewer's report:
Grammar and Experimental Concerns Summary
1. Randomization methodology is unclear.
2. Sample size is relatively small, and power calculation is missing.
3. Results interpretation should focus more on statistically significant findings.
4. Sentence structure and punctuation need improvement.
Recommendations
• Clarify randomization process and consider power calculations.
• Strengthen discussion of mechanistic insights and the clinical significance of findings.
• Simplify sentence structure and ensure consistent punctuation and tense usage.
Review for 10.1186/s12876-024-03498-z (2024)

Title: The mechanism of transcutaneous gastric pacing treatment on gastrointestinal motility
recovery and inflammation improvement in early-stage acute pancreatitis patients
Version: 1 Date: 15 Oct 2024
Reviewer:  Heithem Soliman
Reviewer's report:
Most of the comments have been addressed. However, one major issue about the
overinterpretation of the results remains problematic. The results in the abstract are even less
clear, and presented in a incorrect setting. I think that only the results after gastric pacing, and
after the conventional treatment. While before and after the treatments, the changes can be
related to the natural evolution of the disease.
Review for 10.1186/s12876-024-03498-z (2024)

Title: The mechanism of transcutaneous gastric pacing treatment on gastrointestinal motility
recovery and inflammation improvement in early-stage acute pancreatitis patients
Version: 1 Date: 23 Oct 2024
Reviewer's report:
Hello authors,
Thank you for the study. This was interesting study with findings and mechanisms of
interventions.
I think this is something that could be applied for the greater population.
Review for 10.1186/s12876-024-03498-z (2024)

Title: The mechanism of transcutaneous gastric pacing treatment on gastrointestinal motility
recovery and inflammation improvement in early-stage acute pancreatitis patients
Version: 2 Date: 30 Oct 2024
Reviewer:  Heithem Soliman
Reviewer's report:
My comments have been adressed. I would just have moved the sample size calcultation to the
"statistical analysis" subsection.
Otherwise, the presentation is more accurate yet.
Review for 10.1186/s12876-024-03496-1 (2024)

Title: Efficacy and safety of tanshinone IIA in combination with mesalazine in the treatment of
ulcerative colitis: a Systematic review and meta-analysis
Version: 1 Date: 04 Sep 2024
Reviewer:  Patroklos Katafygiotis
Reviewer's report:
The combination of treatments that have been tested by the Chinese and Western medical
communities are of particular interest.
I would like to point out some points that need improvement:
1. In the sentence "Tanshinone IIA injection is the kind of TCM that have the effect at reducing
the manufacture of the inflammatory cells and can downward the advancement of inflammation
and improve the immunity capability of body" the word "manufacture" needs to be changed.
2. Paragraph 2.5 needs several corrections to be understood.
3. I think that a paragraph is needed in the “Discussion” in which a more extensive description
of the drug "tanshinone IIA" is given and the reason why the other forms of tanshinone
( dihydrotanshinone, tanshinone I) could not be used in the treatment of UC.
Review for 10.1186/s12876-024-03496-1 (2024)

Title: Efficacy and safety of tanshinone IIA in combination with mesalazine in the treatment of
ulcerative colitis: a Systematic review and meta-analysis
Version: 2 Date: 04 Oct 2024
Reviewer:  Patroklos Katafygiotis
Reviewer's report:
Very interesting work. I would like to point out two phrases that could be written differently to
better fit the scientific article.
These are: 1. malignant tendencies (in the first paragraph of Introduction)
2.Killing ability on bacteria (in the initial part of the Discussion)
Review for 10.1186/s12876-024-03496-1 (2024)

Title: Efficacy and safety of tanshinone IIA in combination with mesalazine in the treatment of
ulcerative colitis: a Systematic review and meta-analysis
Version: 2 Date: 08 Oct 2024
Reviewer's report:
Regarding comment 5 authors haven't assessed this intervention so not fully getting the value
of keeping the sentence
Discussion needs improvement and more discussion of included studies and previous literature
conclusion could be more concise but comprehensive
Review for 10.1186/s12876-024-03496-1 (2024)

Title: Efficacy and safety of tanshinone IIA in combination with mesalazine in the treatment of
ulcerative colitis: a Systematic review and meta-analysis
Version: 3 Date: 20 Oct 2024
Reviewer:  Patroklos Katafygiotis
Reviewer's report:
there is a spelling mistake that I have marked in blue
Review for 10.1186/s12876-024-03494-3 (2024)

Title: Risk factors and prognostic impact of new decompensated events in hospitalized patients
with decompensated cirrhosis
Version: 1 Date: 06 Oct 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
Number of patients should be removed from methods section both in the abstract and the
relevant section of the text Methods Authors should define if the term HE covers both overt
and covert one Comorbidities should be defined further Were patients on any stool softeners
for constipation? Electrolytic imbalance should be mentioned Follow-up time-points should be
defined Tuberculosis should be mentioned and its diagnostic process should be defined Results
numerical values of laboratory parameters differing between patients with and without further
decompensation should be reported
Review for 10.1186/s12876-024-03494-3 (2024)

Title: Risk factors and prognostic impact of new decompensated events in hospitalized patients
with decompensated cirrhosis
Version: 2 Date: 17 Oct 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
The study verifies data already known in medical literature  Methods underlined comorbidities
should be defined
Review for 10.1186/s12876-024-03494-3 (2024)

Title: Risk factors and prognostic impact of new decompensated events in hospitalized patients
with decompensated cirrhosis
Version: 2 Date: 21 Oct 2024
Reviewer's report:
The authors added more information after this review round.
I think that the paper has been improved, even if important limitations (low number of patients,
single center study) still remain. Moreover, I think that the study did not add significant novelties
on this field.
Review for 10.1186/s12876-024-03494-3 (2024)

Title: Risk factors and prognostic impact of new decompensated events in hospitalized patients
with decompensated cirrhosis
Version: 3 Date: 31 Oct 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
Authors have applied all changes requested Thus the study is ready for publication
Review for 10.1186/s12876-024-03495-2 (2024)

Title: Investigating the Diagnostic and Prognostic Significance of Genes Related to Fatty Acid
Metabolism in Hepatocellular Carcinoma
Version: 3 Date: 16 Aug 2024
Reviewer's report:
The manuscript investigated the role of FA metabolism-related genes in HCC. The identification
of potential diagnostic and prognostic biomarkers, along with the experimental validation of
SLC22A1, offers promising a valuable contribution in the field of HCC studies. I recommend
this manuscript for acceptance.
Review for 10.1186/s12876-024-03495-2 (2024)

Title: Investigating the Diagnostic and Prognostic Significance of Genes Related to Fatty Acid
Metabolism in Hepatocellular Carcinoma
Version: 3 Date: 10 Sep 2024
Reviewer:  Anwar Ashraf Abouelnasr
Reviewer's report:
changes are done, accepted for publication
Review for 10.1186/s12876-024-03495-2 (2024)

Title: Investigating the Diagnostic and Prognostic Significance of Genes Related to Fatty Acid
Metabolism in Hepatocellular Carcinoma
Version: 3 Date: 11 Sep 2024
Reviewer's report:
This paper systematically identified a signature of FA-related genes in patients with HCC using
WGCNA and predicted a diagnostic and prognostic model to establish the relationship between
FA metabolism and HCC. Finally, the expression level of the selected gene of SLC22A1
were verified in two HCC cell lines. The following concerns should be clarified before further
consideration:
1. There are some errors in grammar and spelling, such as "foetal bovine serum ", " utilised,
generalised and personalised etc.". It would be more readable if revising it.
2. Is there any published evidence supporting the results that SLC22A1 is associated with FAs
metabolism in HCC? Could you clarify the rationale for selecting SLC22A1? These insights
should be addressed in the introduction section.
3. Why was the Random Forest model used to identify five genes that do not overlap with the
four genes included in the risk score formula? Additionally, what is the significance of the newly
identified gene, CYS2?
4. Please explain how Weighted Gene Co-expression Network Analysis can be utilized to verify
the adequacy of the model in supporting the stated hypothesis?
5. Given the relationship between FAs metabolism and HCC, could you explain the rationale
behind choosing the SNU-449 and SNU398 cell lines to verify the expression levels of
SLC22A1? This explanation would be beneficial in the discussion section.